Therapeutic Area: Oncology
Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells
Authors and Affiliates
Nils-Petter Rudqvist1, Karsten A. Pilones1, Claire Lhuillier1, Erik Wennerberg1, John-William Sidhom2, Ryan O. Emerson3, Harlan S. Robins3,4, Jonathan Schneck2, Silvia C. Formenti1, Sandra Demaria1,5
1Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA, 2Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 3Adaptive Biotechnologies, 1551 Eastlake Ave. E, Seattle, WA 98102, USA, 4Public Health Sciences Division, Fred Hutchinson Cancer Research, 100 Fairview Ave. N., Seattle, WA 98109, USA, 5Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA
T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire
Authors and Affiliates
Beausang JF1, Wheeler AJ2, Chan NH2, Hanft VR2, Dirbas FM2, Jeffrey SS2, Quake SR3,4,5;
1
Department of Bioengineering, Stanford University, Stanford, CA 94305.
2
Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305.
3
Department of Bioengineering, Stanford University, Stanford, CA 94305; quake@stanford.edu.
4
Department of Applied Physics, Stanford University, Stanford, CA 94305.
5
Chan Zuckerberg Biohub, San Francisco, CA 94518.
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Authors and Affiliates
Stromnes IM1,2, Hulbert A3,2, Pierce RH3,2, Greenberg PD1,2,4, Hingorani SR1,4,5;
1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. ingunn@umn.edu pgreen@uw.edu srh@fhcrc.org.
2
Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
3
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
4
Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington.
5
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab
Reuben et al.
OncoImmunology
Papers
October 2017
Authors and Affiliates
Alexandre Reubena, Mariana Petaccia de Macedob, Jennifer McQuadec, Aron Joond, Zhiyong Rene,Tiffany Calderoneb, Brandy Connerb, Khalida Wanib, Zachary A. Coopera,f,z, Hussein Tawbic, Michael T. Tetzlaffb,e, Robert F. Paderag, Jean-Bernard Durandh, Alexander J. Lazarb,e, Jennifer A. Wargoa,f, and Michael A. Daviesb,c,i
aDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; bTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; cMelanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; dBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; ePathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; fGenomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; gDepartment of Pathology, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA; hCardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; iSystems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
Reuben et al.
Cancer Discovery
Papers
October 2017
Authors and Affiliates
Alexandre Reuben1,2, Rachel Gittelman3, Jianjun Gao4, Jiexin Zhang5, Erik C. Yusko3, Chang-Jiun Wu2, Ryan Emerson3, Jianhua Zhang2, Christopher Tipton3, Jun Li2, Kelly Quek2,6, Vancheswaran Gopalakrishnan1, Runzhe Chen2,6, Luis M. Vence7, Tina Cascone6, Marissa Vignali3, Junya Fujimoto8, Jaime Rodriguez-Canales8, Edwin R. Parra8, Latasha D. Little2, Curtis Gumbs2, Marie-Andrée Forget9, Lorenzo Federico9, Cara Haymaker9, Carmen Behrens8, Sharon Benzeno3, Chantale Bernatchez9, Boris Sepesi10, Don L. Gibbons6, Jennifer A. Wargo1,2, William N. William Jr6, Stephen Swisher10, John V. Heymach6, Harlan Robins3,11, J. Jack Lee12, Padmanee Sharma4,7, James P. Allison7, P. Andrew Futreal2, Ignacio I. Wistuba8, and Jianjun Zhang2,6
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3Adaptive Biotechnologies, Seattle, Washington. 4Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6Department of Thoracic/Head and Neck Medical Oncology, The Univer- sity of Texas MD Anderson Cancer Center, Houston, Texas. 7Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9Department of Melanoma Medical Oncology, The University of Texas MD Ander- son Cancer Center, Houston, Texas. 10Department of Thoracic Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 11Department of Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington. 12Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response
Soukup et al.
Papers
Scientific Reports
September 2017
Authors and Affiliates
Klara Soukup1,4, Angela Halfmann1, Barbara Dillinger1, Fiona Poyer1, Katharina Martin1, Bernadette Blauensteiner1, Maximilian Kauer2, Mario Kuttke3, Gernot Schabbauer3 & Alexander M. Dohnal1,5
1Tumour Immunology, St. Anna Kinderkrebsforschung, Children’s Cancer Research Institute, Vienna, Austria. 2Bioinformatics, St. Anna Kinderkrebsforschung, Children’s Cancer Research Institute, Vienna, Austria. 3Institute for Physiology, Centre for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. 4Present address: Department of Fundamental Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. 5Present address: APEIRON Biologics AG, Vienna, Austria
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade
Authors and Affiliates
Dung T. Le,1,2,3 Jennifer N. Durham,1,2,3 Kellie N. Smith,1,3 Hao Wang,3 Bjarne R. Bartlett,2,4 Laveet K. Aulakh,2,4 Steve Lu,2,4 Holly Kemberling,3 Cara Wilt,3 Brandon S. Luber,3 Fay Wong,2,4 Nilofer S. Azad,1,3 Agnieszka A. Rucki,1,3 Dan Laheru,3 Ross Donehower,3 Atif Zaheer,5 George A. Fisher,6 Todd S. Crocenzi,7 James J. Lee,8 Tim F. Greten,9 Austin G. Duffy,9 Kristen K. Ciombor,10 Aleksandra D. Eyring,11 Bao H. Lam,11 Andrew Joe,11 S. Peter Kang,11 Matthias Holdhoff,3 Ludmila Danilova,1,3 Leslie Cope,1,3 Christian Meyer,3 Shibin Zhou,1,3,4 Richard M. Goldberg,12 Deborah K. Armstrong,3 Katherine M. Bever,3 Amanda N. Fader,13 Janis Taube,1,3 Franck Housseau,1,3 David Spetzler,14 Nianqing Xiao,14 Drew M. Pardoll,1,3 Nickolas Papadopoulos,3,4 Kenneth W. Kinzler,3,4 James R. Eshleman,15 Bert Vogelstein,1,3,4 Robert A. Anders,1,3,15 Luis A. Diaz Jr.1,2,3
1Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA. 2Swim Across America Laboratory at Johns Hopkins, Baltimore, MD 21287, USA. 3Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA. 4Ludwig Center and Howard Hughes Medical Institute at Johns Hopkins, Baltimore, MD 21287, USA. 5Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. 6Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. 7Providence Cancer Center at Providence Health & Services, Portland, OR 97213, USA. 8Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA. 9Gastrointestinal Malignancies Section, Thoracic-GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. 10Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. 11Merck & Co. Inc., Kenilworth, NJ 07033, USA. 12West Virginia University Cancer Institute, Morgantown, WV 26506, USA. 13Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, MD 21287, USA. 14Caris Life Sciences, Phoenix, AZ 85040, USA. 15Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
Radwan et al.
BMC Cancer
Papers
August 2017
Authors and Affiliates
Noura Radwan1, Ryan Phillips1, Ashley Ross2,3, Steven P. Rowe4, Michael A. Gorin3, Emmanuel S. Antonarakis2, Curtiland Deville1,2, Stephen Greco1, Samuel Denmeade2,3, Channing Paller2, Daniel Y. Song1,2,3, Maximilian Diehn5, Hao Wang2, Michael Carducci2,3, Kenneth J. Pienta2,3, Martin G. Pomper1,2,3,4, Theodore L. DeWeese1,2,3,
Adam Dicker6, Mario Eisenberger2,3 and Phuoc T. Tran1,2,3
1Department of Radiation Oncology & Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231, USA. 2Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5Department of Radiation Oncology, Stanford University, Stanford, CA, USA. 6Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Jiménez-Sánchez et al.
Cell
Papers
August 2017
Authors and Affiliates
Alejandro Jiménez-Sánchez,1 Danish Memon,1,2 Stephane Pourpe,10 Harini Veeraraghavan,3 Yanyun Li,4 Hebert Alberto Vargas,5 Michael B. Gill,1 Kay J. Park,6 Oliver Zivanovic,7 Jason Konner,8 Jacob Ricca,4 Dmitriy Zamarin,4,10 Tyler Walther,10 Carol Aghajanian,8 Jedd D. Wolchok,4,9,10,11,12 Evis Sala,5 Taha Merghoub,4 Alexandra Snyder,10,11 and Martin L. Miller1
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK, 2European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK, 3Department of Medical Physics, 4Ludwig Collaborative/Swim Across America Laboratory, 5Department of Radiology, 6Department of Pathology, 7Gynecology Service, Department of Surgery, 8Gynecologic Medical Oncology Service, Department of Medicine, 9Parker Institute for Cancer Immunotherapy, 10Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA, 11Department of Medicine, Weill Cornell Medical College, New York, NY, USA, 12Immunology and Microbial Pathogenesis Programs, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA